CLINICAL TRIALS PROFILE FOR SARAFEM
✉ Email this page to a colleague
All Clinical Trials for Sarafem
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00339079 ↗ | Treatment of Hypochondriasis With CBT and/or SSRI | Completed | National Institute of Mental Health (NIMH) | Phase 1/Phase 2 | 2006-06-01 | This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis. |
| NCT00339079 ↗ | Treatment of Hypochondriasis With CBT and/or SSRI | Completed | Brigham and Women's Hospital | Phase 1/Phase 2 | 2006-06-01 | This study will compare the effectiveness of cognitive behavioral therapy, antidepressant medication, and a combination of the two for treating hypochondriasis. |
| NCT00678574 ↗ | The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 1998-03-01 | The purpose of the study proposed is to investigate the role of neurosteroids and GABA in the pathophysiology and treatment of premenstrual dysphoric disorder (PMDD) by 1) measuring cortical gama-aminobutyric acid levels (GABA levels) using nuclear magnetic resonance spectroscopy (MRS) during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®, Sarafem®), and 2) correlating cerebrospinal fluid (CSF) and plasma GABA and neurosteroid levels with cortical GABA levels at these same time points. Neurosteroids to be measured include allopregnanolone, pregnenolone, and pregnenolone sulfate. Findings from women with PMDD will be compared to those of healthy subjects. |
| NCT00678574 ↗ | The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder | Completed | University of Pennsylvania | Phase 4 | 1998-03-01 | The purpose of the study proposed is to investigate the role of neurosteroids and GABA in the pathophysiology and treatment of premenstrual dysphoric disorder (PMDD) by 1) measuring cortical gama-aminobutyric acid levels (GABA levels) using nuclear magnetic resonance spectroscopy (MRS) during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®, Sarafem®), and 2) correlating cerebrospinal fluid (CSF) and plasma GABA and neurosteroid levels with cortical GABA levels at these same time points. Neurosteroids to be measured include allopregnanolone, pregnenolone, and pregnenolone sulfate. Findings from women with PMDD will be compared to those of healthy subjects. |
| NCT01174394 ↗ | Electroacupuncture Combined With Antidepressants for Post-stroke Depression | Completed | Kowloon Hospital, Hong Kong | N/A | 2010-05-01 | This is a randomized, assessor-blind, placebo controlled study in post stroke depression patients. Subjects receiving antidepressant drug would be assigned to either active or placebo scalp electro-acupuncture treatment, on the hypothesis that acupuncture intervention combined with antidepressants could produce greater therapeutic effects than antidepressants alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Sarafem
Condition Name
Clinical Trial Locations for Sarafem
Trials by Country
Clinical Trial Progress for Sarafem
Clinical Trial Phase
Clinical Trial Sponsors for Sarafem
Sponsor Name
